Germany · Delayed Price · Currency is EUR SCYNEXIS Company Description
SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States.
It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC.
The company’s lead product candidate is Ibrexafungerp, a drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.
It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No.
3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, CJSC (R-Pharm), and Cypralis Limited for the development, manufacture, and commercialization of ibrexafungerp.
SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002.
The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
| Country | United States |
| Founded | 1999 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 28 |
| CEO | David Angulo |
Contact Details
Address: 1 Evertrust Plaza Jersey City, Delaware 07302-6548 United States | |
| Phone | 201 884 5485 |
| Website | scynexis.com |
Stock Details
| Ticker Symbol | 135A |
| Exchange | Frankfurt Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| David Angulo | Chief Executive Officer |
| Ivor Macleod | Chief Financial Officer |